---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-093684"
form_type: "8-K"
ticker: "APGE"
cik: "0001974640"
company_name: "Apogee Therapeutics, Inc."
filed_at: "2023-08-21T23:59:59+00:00"
generated_at: "2026-06-11T06:33:12.338071+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Apogee Therapeutics appoints Mark C. McKenna as Chairman of Board

## Summary
- Mark C. McKenna appointed as Chairman and Class III director, effective August 17, 2023.
- Former President, CEO, and Chairman of Prometheus Biosciences, acquired by Merck for ~$10.8B.
- Previously President of Salix Pharmaceuticals and senior roles at Bausch + Lomb and Johnson & Johnson.
- Annual compensation of $84,000 for Chair and committee roles; options for 50,000+100,000 shares vesting over 3 years.
- McKenna holds B.S. from Arizona State and MBA from Azusa Pacific; brings I&I development and commercial expertise.

## SEC filing metadata
- accession: 0001104659-23-093684
- form_type: 8-K
- ticker: APGE
- cik: 0001974640
- company_name: Apogee Therapeutics, Inc.
- filed_at: 2023-08-21T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1974640/000110465923093684/0001104659-23-093684-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1974640/000110465923093684/tm2324210d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-093684
- JSON: https://secwatch.observer/filing/0001104659-23-093684.json
- Plain text: https://secwatch.observer/filing/0001104659-23-093684.txt

## Key facts
- Executive change
  Mark C. McKenna was appointed as Chair of the Board at Apogee Therapeutics, Inc..
  - Action: appointed
  - Role: Chair of the Board
  source text: On August 17, 2023, the board of directors (the “Board”) of Apogee Therapeutics, Inc. (the “Company”) appointed Mark C. McKenna as a member of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1974640/000110465923093684/0001104659-23-093684-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.